After Integra LifeSciences released a warning letter it received from the FDA relating to its Puerto Rico facility, RBC Capital expects the company to address the issue fairly quickly. If management follows the process outlined in its guidance, the firm thinks the impact on the company's Q1 results will be "minimal." It maintains a Sector Perform rating on the stock.
- Investment & Company Information
- Integra LifeSciences